T Cell Activation Assay for Predicting Antibody Immunogenicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for determining the propensity of therapeutics to elicit anti-drug antibodies (ADAs) are labor-intensive, time-consuming, and costly, requiring expensive equipment, limiting their efficiency in preclinical drug development.

Innovation Solution

A method involving culturing lymphocytes in the presence and absence of a composition to generate stimulated and unstimulated cells, determining the expression of CD134 and CD137 markers, and calculating a stimulation index to assess the propensity for ADA production, which can be done with lymphocytes from a single donor or multiple donors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If MAPPs or T cell proliferation assays are used to determine immunogenic potential, then measurement precision is improved, but device complexity and loss of time increase

Engineering Contradiction:

Improveimmunogenic potential assessmentVSAvoidassay duration

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent segments the complex immunogenicity assessment into distinct functional components: (1) APC incubation with therapeutic candidate, (2) T cell co-culture and stimulation, (3) Activation marker detection via flow cytometry, and (4) Stimulation index calculation. This segmentation enables parallel processing and optimization of each step, reducing overall assay time while maintaining precision through standardized protocols for each segment.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies preliminary action by pre-characterizing activation markers (CD134, CD137, CD69) on T cells before the actual immunogenicity test. This preliminary setup includes establishing baseline expression levels and optimizing antibody concentrations for detection, which streamlines the main assay execution and reduces time during the critical measurement phase while ensuring precise detection capabilities are in place.

Inventive Principle:

Principle #10Preliminary action

2Measurement precision

If MAPPs or T cell proliferation assays are used to determine immunogenic potential, then measurement precision is improved, but device complexity increases

Engineering Contradiction:

Improveimmunogenic potential assessmentVSAvoidequipment requirements

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent replaces complex mechanical and computational systems (LC/MS for MAPPs, proliferation detection equipment) with flow cytometry-based detection of activation markers. This substitution maintains measurement precision by directly detecting T cell activation states through fluorescently labeled antibodies, while dramatically simplifying the equipment needed—requiring only a flow cytometer rather than sophisticated mass spectrometry or proliferation assay systems.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces activation markers (CD134, CD137, CD69) as intermediaries between the therapeutic candidate and the detection system. These markers serve as measurable proxies for T cell activation, allowing indirect but precise assessment of immunogenic potential through flow cytometry. This intermediary approach simplifies the measurement system compared to direct detection methods while maintaining or improving precision through the use of well-characterized molecular markers.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Measurement precision

If MAPPs or T cell proliferation assays are used to determine immunogenic potential, then measurement precision is improved, but productivity decreases

Engineering Contradiction:

Improveimmunogenic potential assessmentVSAvoidscreening throughput

Core Design Contradiction:

Measurement precisionVSProductivity

Solution Approach 1:

The patent segments the assessment protocol to enable high-throughput processing, with standardized incubation times, cell ratios, and detection parameters that can be replicated across multiple samples simultaneously. The flow cytometry-based approach allows parallel analysis of multiple T cell populations and therapeutic candidates, dramatically increasing screening throughput compared to sequential MAPPs or proliferation assays while maintaining precise measurement of each sample's immunogenic potential.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a more efficient and cost-effective means to predict the immunogenic potential of therapeutics, correlating with clinical outcomes and reducing the risk of adverse events by identifying compositions with lower ADA elicitation propensity.

Implementation Method 1

culturing lymphocytes in the presence of the composition to generate stimulated lymphocytes

Methodology Applied

Scientific EffectT cell activation:

Implementation Method 2

determining the percentage of the stimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137

Methodology Applied

Scientific EffectFlow cytometry:

Data Source

PatentUS20230184747A1T cell-based methods for predicting polypeptide immunogenicity

Publication Date: 2023.06.15 GENENTECH INC

AI summary

The presently disclosed subject matter provides methods for determining the propensity of a composition, e.g., a composition comprising an antibody or a fragment thereof, to elicit production of anti-drug antibodies (ADAs) and kits for performing such methods.